---
title: "Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market"
description: "Maxwell Skor has issued a Buy rating for Cidara Therapeutics, highlighting its antiviral candidate CD388, which targets the $5 billion influenza market. CD388 offers a single-dose prevention option an"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261401126.md"
published_at: "2025-10-16T08:55:41.000Z"
---

# Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market

> Maxwell Skor has issued a Buy rating for Cidara Therapeutics, highlighting its antiviral candidate CD388, which targets the $5 billion influenza market. CD388 offers a single-dose prevention option and is expected to show broad protection in Phase 3 data due in June 2026. The drug has received FDA Fast Track and Breakthrough Therapy designations, and positive Phase 2b results support its potential. Cidara's strong financial position enhances its attractiveness as an investment, with J.P. Morgan also initiating coverage with a Buy rating and a $200 price target.

Maxwell Skor has given his Buy rating due to a combination of factors surrounding Cidara Therapeutics and its promising lead candidate, CD388. This long-acting antiviral is positioned as a significant player in the influenza prophylaxis market, offering a single-dose prevention option that complements existing vaccines and serves as a standalone alternative for certain populations. The anticipated Phase 3 interim data in June 2026 is expected to highlight CD388’s broad protection and season-long durability, which are key differentiators in the market.  
Skor’s confidence is further bolstered by CD388’s FDA Fast Track and Breakthrough Therapy designations, along with positive Phase 2b results. The drug targets a sizable market opportunity of over $5 billion, addressing a broad population in the U.S., including those who are poor vaccine responders or have an aversion to vaccination. With Cidara’s strong financial position, evidenced by their substantial cash reserves, the company is well-equipped to advance through the Phase 3 program, making it an attractive investment opportunity.

In another report released on October 10, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $200.00 price target.

### Related Stocks

- [CDTX.US - Cidara Therap](https://longbridge.com/en/quote/CDTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cidara Therapeutics Completes Acquisition and Becomes Private Company | Cidara Therapeutics has completed its acquisition, becoming a private company after a cash tender offer for approximatel | [Link](https://longbridge.com/en/news/271805051.md) |
| Cidara’s Phase III trial of CD388 reaches target enrolment | Cidara Therapeutics has achieved its target enrolment of 6,000 patients in the Phase III ANCHOR trial of CD388, aimed at | [Link](https://longbridge.com/en/news/267321362.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins | Nuclera and leadXpro have announced a partnership to enhance structure-based drug design for complex membrane proteins.  | [Link](https://longbridge.com/en/news/276109364.md) |
| 11:08 ETAmericans Wash Hands More During Flu Season but Everyday Habits Still Fall Short, New Survey Finds | A recent survey reveals that 70% of Americans are concerned about contracting the flu, up from 59% three years ago. The  | [Link](https://longbridge.com/en/news/275633689.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.